CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
Bharat Forge Ltd. 25/07/20241,593.85952.3007/04/2025 -40.25% 256 days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Buzzing Stocks: Globus Spirits and Piramal Enterprises in news
DSIJ Intelligence
/ Categories: Trending, Mindshare

Buzzing Stocks: Globus Spirits and Piramal Enterprises in news

Shares of Globus Spirits skyrocketed by more than 10 per cent to touch an intra-day high of Rs 1,299.90 per share on NSE. Scrip of Piramal Enterprises climbed more than 4 per cent during early markets to record an intra-day high of Rs 2,554 per share on NSE.

Globus Spirits – The company has informed the exchange that the expansion of the company's unit located at Panagarh, Burdwan, West Bengal is complete as per the schedule and the unit is now running at its enhanced capacity of 260 KLPD (kilolitre per day) enhanced from 120 KLPD. 

Shares of Globus Spirits skyrocketed by more than 10 per cent to touch an intra-day high of Rs 1,299.90 per share on NSE.

Piramal Enterprises – The company’s subsidiary, Piramal Pharma Limited (PPL), has entered into agreements and acquired a 27.78 per cent stake in Yapan Bio Private Limited for an investment of Rs. 101.77 crores (cash consideration). Yapan is a contract development and manufacturing organization (CDMO) in Hyderabad, providing process development, scale-up and complaint GMP manufacturing of vaccines and biologics/bio-therapeutics for human clinical trials across the world. The company is augmenting the capabilities of its contract development and manufacturing organization business, Piramal Pharma Solutions (PPS).                                      

Capabilities at Yapan include development and GMP facilities for high containment product classes (up to BSL2+). Yapan’s turnover during FY21 stood at Rs 12.4 crore. PPS currently offers integrated payload, conjugation, fill-finish services, and the addition of anti-body capabilities enhances that offering.

To quote an excerpt from the company’s filing with the exchange, “In today’s market, many pharma innovator companies are looking for CDMOs to support their biologics development and manufacturing requirements. PPS expects that adding these capabilities and expertise will enable the company to further enhance its offerings in this attractive, fast-track growth sector.”

Scrip of Piramal Enterprises climbed more than 4 per cent during early markets to record an intra-day high of Rs 2,554 per share on NSE.

Keep a close eye on these counters today!

Previous Article Five stocks witnessing short build-up
Next Article Shares below Rs 100: These stocks are locked in the upper circuit on Tuesday!
Print
463 Rate this article:
3.5
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR